Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Phase 3

Terminated

• Conditions: Chronic Myeloid Leukemia
• Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)

• Registration Number: NCT01650805
• Lead Sponsor: Ariad Pharmaceuticals

Brief Summary

The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

Detailed Description

This multicenter, international, phase 3 trial will test the hypothesis that ponatinib is an effective treatment for newly diagnosed CP-CML patients when compared with standard imatinib.

Patients will be randomized in a 1:1 fashion, stratified by Sokal risk score at diagnosis (low, intermediate, high), to receive once daily oral administration of either ponatinib or imatinib. Efficacy measures include molecular, cytogenetic, and hematologic response rates at various timepoints; time to, duration of, and durability of responses; and survival follow-up. Safety measures include clinical laboratory testing, adverse event monitoring, vital signs, physical exams, ECGs, and ECHOs. Other measures include two patient-reported health outcomes questionnaires (FACT-Leu and EQ-5D-5L), determination of mutation status, and, for ponatinib only, measurement of steady-state plasma concentration. Accrual is expected to take approximately 2 years, and patients will be followed for survival for up to 8 years after the last patient's first dose; therefore, patient participation may last up to 10 years.

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-07-18
• Study First Submitted QC: 2012-07-24
• Study First Posted: 2012-07-26
• Primary Completion: 2013-10
• Study Completion: 2013-10
• Status Verified: 2014-10
• Results First Submitted: 2014-10-15
• Results First Submitted QC: 2014-10-15
• Results First Posted: 2014-10-21
• Last Update Submitted: 2014-11-05
• Last Update Posted: 2014-11-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 307

Inclusion Criteria

1. CP CML within 6 months of diagnosis

   • CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) ≥100 × 10^9/L platelets (≥100,000/mm^3); (v) No evidence of extramedullary disease except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML

2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22) Philadelphia chromosome

   • (a)Variant translocations are only allowed provided they are assessable for cytogenetic response utilizing conventional cytogenetic techniques; (b) Conventional chromosome banding must be performed; AND (c) A minimum of 20 metaphases must be assessable at entry

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

4. Adequate hepatic function as defined by the following criteria:

   (a) Total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome; (b) Alanine aminotransferase (ALT) ≤2.5 × ULN; AND (c) Aspartate aminotransferase (AST) ≤2.5 × ULN

5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN

6. Adequate pancreatic function as defined by serum lipase and amylase ≤1.5 × ULN

Exclusion Criteria

1. Received prior imatinib therapy

2. Received prior dasatinib therapy

3. Received prior nilotinib therapy

4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or radiation therapy with the exception of anagrelide or hydroxyurea

5. Major surgery within 28 days prior to initiating therapy

6. History of bleeding disorder unrelated to CML

7. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis

8. History of alcohol abuse

9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)

10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

    1. Myocardial infarction, within 6 months prior to randomization
    2. Unstable angina within 6 months prior to randomization
    3. Congestive heart failure within 6 months prior to randomization
    4. History of clinically significant (as determined by the treating physician) atrial arrhythmia or any ventricular arrhythmia
    5. Any history of ventricular arrhythmia
    6. Cerebrovascular accident or transient ischemic attack within 6 months prior to randomization
    7. Any history of peripheral arterial occlusive disease requiring revascularization
    8. Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism

11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control

12. Taking medications that are known to be associated with Torsades de Pointes

13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection

14. Known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history

15. Pregnant or breastfeeding

16. Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs

17. Diagnosed with or received anticancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)

18. Any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ponatinib	ponatinib	-
imatinib	imatinib (Gleevec/ Glivec)	-

Primary Outcome Measures

Name	Time	Method
Major Molecular Response (MMR) Rate at 12 Months	12 months after first dose	A ratio of reverse transcribed transcript of BCR-ABL to ABL ≤ 0.1% on the international scale, measured by real-time quantitative polymerase chain reaction.

Secondary Outcome Measures

Name	Time	Method
MMR Rate	5 years after first dose	To compare the efficacy of ponatinib with imatinib, as measured by MMR rate, at 5 years
<10% BCR-ABL^IS Rate	3 months after first dose	To compare the proportion of patients achieving a ratio of \<10% BCR-ABL to ABL transcript levels at 3 months, as measured by the international scale (\<10% BCR-ABL\^IS), in patients administered ponatinib versus those administered imatinib
Complete Cytogenetic Response (CCyR) Rate	12 months after first dose	The percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. Responses are defined as follows: Complete (CCyR): 0% Ph+ metaphases.
Progression-free Survival	Up to 8 years after the last patient's first dose	To compare, according to treatment with ponatinib versus imatinib, progression-free survival
Overall Survival	Up to 8 years after the last patient's first dose	To compare, according to treatment with ponatinib versus imatinib, overall survival

Trial Locations

Locations (170)

US Oncology - Providence Health System, Site #167; 🇺🇸 Burbank, California, United States

UCLA Department of Medicine, Site #027; 🇺🇸 Los Angeles, California, United States

Bay Area Cancer Research Group, Site #156; 🇺🇸 Pleasant Hill, California, United States

Bay Area Cancer Research Group, Site #157; 🇺🇸 Pleasant Hill, California, United States

Rocky Mountain Cancer Centers, Site #191; 🇺🇸 Boulder, Colorado, United States

Cancer Center of Central Connecticut, Site #147; 🇺🇸 Southington, Connecticut, United States

Christiana Care Health Services, Site #155; 🇺🇸 Newark, Delaware, United States

University Cancer Institute, Site #149; 🇺🇸 Boynton Beach, Florida, United States

Florida Cancer Specialists, Site #180; 🇺🇸 Fort Meyers, Florida, United States

Florida Cancer Specialists, Site #179; 🇺🇸 St. Petersburg, Florida, United States

Scroll for more (160 remaining)